Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,100
  • Shares Outstanding, K 31,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,470 K
  • EBIT $ -62 M
  • EBITDA $ -62 M
  • 60-Month Beta -0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.47
  • Number of Estimates 4
  • High Estimate -0.30
  • Low Estimate -0.62
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +9.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +31.58%
on 12/13/24
2.34 -14.53%
on 12/05/24
-0.04 (-1.96%)
since 11/20/24
3-Month
1.52 +31.58%
on 12/13/24
3.35 -40.30%
on 09/23/24
-1.21 (-37.69%)
since 09/20/24
52-Week
1.00 +100.00%
on 08/16/24
7.92 -74.75%
on 12/28/23
-4.70 (-70.15%)
since 12/20/23

Most Recent Stories

More News
Immuneering Corporation Forms Pancreatic Cancer Advisory Board to Advance IMM-1-104 Development

Immuneering Corporation establishes a Pancreatic Cancer Advisory Board to enhance clinical guidance for its lead candidate, IMM-1-104.Quiver AI SummaryImmuneering Corporation has established a Pancreatic...

IMRX : 2.00 (+8.70%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.8310 (-6.36%)
PYXS : 1.6900 (+9.74%)
RPTX : 1.3200 (unch)
IMRX : 2.00 (+8.70%)
CVM : 0.7299 (-4.60%)
ONC.TO : 1.19 (-9.16%)
Immuneering Launches Pancreatic Cancer Advisory Board

IMRX : 2.00 (+8.70%)
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

IMRX : 2.00 (+8.70%)
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Advanced NRAS-Mutant Melanoma

IMM-1-104 shows promise for melanoma patients after immune checkpoint inhibitors, with favorable tolerability in Phase 1 trials.Quiver AI SummaryImmuneering Corporation announced that its lead candidate...

IMRX : 2.00 (+8.70%)
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

IMRX : 2.00 (+8.70%)
Immuneering Corporation to Present at Piper Sandler 36th Annual Healthcare Conference

Immuneering Corporation will present its oncology pipeline and business strategy at the Piper Sandler Healthcare Conference on December 5, 2024.Quiver AI SummaryImmuneering Corporation, a clinical-stage...

IMRX : 2.00 (+8.70%)
Immuneering to Present at the Piper Sandler 36áµ—Ê° Annual Healthcare Conference

IMRX : 2.00 (+8.70%)
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMRX : 2.00 (+8.70%)
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

IMRX : 2.00 (+8.70%)

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.41
2nd Resistance Point 2.25
1st Resistance Point 2.12
Last Price 2.00
1st Support Level 1.83
2nd Support Level 1.67
3rd Support Level 1.54

See More

52-Week High 7.92
Fibonacci 61.8% 5.28
Fibonacci 50% 4.46
Fibonacci 38.2% 3.64
Last Price 2.00
52-Week Low 1.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar